MedElevator
Войти в исследования Rheumatology (Oxford, England) · 2026
Changing incidence and serotype trends in ANCA-associated vasculitis: a 30-year population-based study in Norfolk, UK.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mukhtyar Chetan B, Ashurst Karen, Coath Fiona L, Ducker Georgina, Fordham Sarah, Kamath Ajay V, Karim Mahzuz, Mooney Janice, Scott David G, Sisson Katherine, Varma Ravi, Watts Richard A
Аннотация
OBJECTIVES: The ANCA associated vasculitides (AAV) are rare diseases with poor outcomes if untreated. Over a 30-year period we have investigated the changing incidence of AAV and its subtypes-granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), eosinophilic GPA (EGPA), proteinase 3 AAV (PR3 AAV), and myeloperoxidase AAV (MPO AAV).
METHODS: The study population included adults in the county of Norfolk, UK between 1991 and 2020. Diagnosis of AAV was made clinically and supported by EMA classification. Classification by ANCA subtype was possible from 2001. The overall incidence of clinical phenotypes GPA, MPA and EGPA, and serological phenotypes PR3 AAV and MPO AAV were analysed for temporal fluctuations and seasonality.
RESULTS: From 1991 to 2020, the incidence (95% CI) of AAV, GPA, MPA and EGPA was 25.1 (22.5, 27.9), 13.6 (11.7, 15.8), 8.5 (7.0, 10.2) and 3.0 (2.1, 4.0) per million person-years, respectively. From 2001 to 2020, the incidence (95% CI) of PR3 AAV and MPO AAV was 11.5 (9.4, 13.9) and 11.7 (9.6, 14.1) per million person-years, respectively. The temporal fluctuations in the incidence of EGPA and PR3 AAV were not significant. The incidence of GPA has a statistical periodicity of 9 years. The incidence of MPO AAV demonstrated a linear rise from 2001 to 2020 (R2 = 0.66). Our patients are getting older at diagnosis. Seasonality was not observed.
CONCLUSION: This is the longest incidence study of AAV in the world. The incidence of GPA showed a 9-year periodicity. The incidence of MPO AAV rose steadily. Its relationship to older age at diagnosis needs formal exploration.
METHODS: The study population included adults in the county of Norfolk, UK between 1991 and 2020. Diagnosis of AAV was made clinically and supported by EMA classification. Classification by ANCA subtype was possible from 2001. The overall incidence of clinical phenotypes GPA, MPA and EGPA, and serological phenotypes PR3 AAV and MPO AAV were analysed for temporal fluctuations and seasonality.
RESULTS: From 1991 to 2020, the incidence (95% CI) of AAV, GPA, MPA and EGPA was 25.1 (22.5, 27.9), 13.6 (11.7, 15.8), 8.5 (7.0, 10.2) and 3.0 (2.1, 4.0) per million person-years, respectively. From 2001 to 2020, the incidence (95% CI) of PR3 AAV and MPO AAV was 11.5 (9.4, 13.9) and 11.7 (9.6, 14.1) per million person-years, respectively. The temporal fluctuations in the incidence of EGPA and PR3 AAV were not significant. The incidence of GPA has a statistical periodicity of 9 years. The incidence of MPO AAV demonstrated a linear rise from 2001 to 2020 (R2 = 0.66). Our patients are getting older at diagnosis. Seasonality was not observed.
CONCLUSION: This is the longest incidence study of AAV in the world. The incidence of GPA showed a 9-year periodicity. The incidence of MPO AAV rose steadily. Its relationship to older age at diagnosis needs formal exploration.